Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHXFree Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

NASDAQ ATHX opened at $0.00 on Wednesday. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99. The firm has a market capitalization of $302,423.10, a P/E ratio of 0.00 and a beta of -0.90.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Recommended Stories

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.